Agency IQ

AUGUST 16, 2024

By Amanda Conti | Aug 13, 2024 10:00 PM CDT Regulatory context: Psychedelic regulation and drug development A growing body of evidence suggests that psychedelics may provide clinical benefit for certain purposes, especially mental health conditions. Read AgencyIQ analysis here for a detailed discussion of these issues. ].

FDA 40

FDA Trials Regulations Therapies 40

Drug Discovery World

JULY 1, 2024

million) to the academy. On the other hand, the Novo Nordisk Foundation Center for Basic Metabolic Research aims to deliver world-class research in tackling some of today’s biggest health challenges. Following its inception, the Novo Nordisk Foundation awarded a grant of DKK 150 million ($21.46

Disease 162

Disease International Research Science 162

The Pharma Data

OCTOBER 14, 2020

“There is an urgent medical need for new treatment options for diuretic-resistant heart failure patients and I look forward to working with the Sequana Medical team and advisors to support the ongoing development of alfa pump DSR to address this need,” said Dr. Felker. and EU5 by 2026. Source link.

Clinical Trials 40

Clinical Trials Clinical Research Therapies FDA 40

Drug Discovery World

FEBRUARY 22, 2024

According to Alzheimer’s Research UK (ARUK): “In the UK, dementia was the leading cause of death in 2022 and has been the leading cause of death for women since 2011 – maintaining its position throughout the Covid-19 pandemic. Dementia is the only major cause of death without a treatment to prevent, slow or stop disease progression. “In

Drugs 147

Drugs Clinical Trials Disease Therapies 147